diplomsko delo
Neja Žnidaršič (Author), Mojca Narat (Mentor)

Abstract

Alzheimerjeva bolezen je najpogostejši vzrok demence in prispeva 60–70 % primerov. Povzročajo jo proteinski skupki imenovani plaki (sestavljeni večinoma iz amiloida ß (Aß)) in nevrofibrilarne pentlje (sestavljene iz proteina tau), ki povzročijo napredujočo sinaptično disfunkcijo in sčasoma smrt nevronov. Za bolezen je značilno napredovanje motnje spomina, kognitivne in osebnostne motnje. Trenutna zdravila zagotavljajo le omejeno zdravljenje simptomov, ne ciljajo pa na glavni vzrok bolezni. Imunoterapija bolnikov z Alzheimerjevo boleznijo zagotavlja nov način specifičnega ciljanja na nevrotoksične učinke Aß, s tem pa poskušamo preprečiti napredovanje bolezni. Imunoterapijo Alzheimerjeve bolezni lahko razdelimo na pasivno in aktivno. Pri pasivni imunizaciji je ideja ta, da bi bolniki prejeli monoklonska protitelesa, ki se vežejo na Aß in nato sprožijo imunski odziv, ki odstrani Aß. Pri aktivni imunizaciji pa bolnike cepijo s cepivi, ki vsebujejo Aß, ta pa bi nato okrepil imunski sistem za ciljanje in odstranjevanje Aß. Trenutno je pasivna imunoterapija obetavnejša kot aktivna, a bo zaradi kompleksnosti Alzheimerjeve bolezni potrebno ponovno oblikovati strategije prihodnjih raziskav v obe smeri imunoterapije, da bomo lahko bolezen preprečili že v zgodnjih fazah.

Keywords

imunoterapija;Alzheimerjeva bolezen;monoklonska protitelesa;cepiva;amiloid beta;protein tau;

Data

Language: Slovenian
Year of publishing:
Typology: 2.11 - Undergraduate Thesis
Organization: UL BF - Biotechnical Faculty
Publisher: [N. Žnidaršič]
UDC: 606:616.8:602.68(043.2)
COBISS: 162529539 Link will open in a new window
Views: 44
Downloads: 10
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Immunotherapy of Alzheimer's disease
Secondary abstract: Alzheimer's disease is the most common cause of dementia, accounting for 60-70% of cases. It is caused by protein aggregates called plaques (composed mainly of amyloid ß (Aß)) and neurofibrillary tangles (composed of tau protein), which cause progressive synaptic dysfunction and eventually neuronal death. The disease is characterised by progressive memory, cognitive and personality impairment. Current drugs provide only limited treatment of symptoms and do not target the underlying cause of the disease. Immunotherapy for AD patients provides a new way to specifically target the neurotoxic effects of Aß in an attempt to prevent disease progression. Immunotherapy for AD can be divided into passive and active immunotherapy. In passive immunisation, the idea is that patients would receive monoclonal antibodies that bind to Aß and then trigger an immune response that removes Aß. In active immunisation, patients are vaccinated with vaccines containing Aß, which would then boost the immune system to target and remove Aß. Currently, passive immunotherapy is more promising than active immunotherapy, but the complexity of AD will require a re-strategisation of future research into both immunotherapy avenues to prevent the disease in its early stages.
Secondary keywords: immunotherapy;Alzheimer's disease;monoclonal antibodies;vaccines;amyloid beta;tau protein;
Type (COBISS): Bachelor thesis/paper
Study programme: 0
Embargo end date (OpenAIRE): 1970-01-01
Thesis comment: Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije
Pages: 1 spletni vir (1 datoteka PDF (VI, 22 str.))
ID: 19853827